Chairman’s Letter
Notes
Bayer Links
Investor Relations
Financial Statements
11. Other operating expenses
| 2006 | 2007 | |
| € million | ||
| Losses from sales of noncurrent assets and from divestitures | (31) | (52) |
| Write-downs of receivables | (138) | (98) |
| Expenses related to significant legal risks | (205) | (139) |
| Recognition of exchange rate hedges | (126) | (57) |
| Miscellaneous operating expenses | (719) | (1,223) |
| Total | (1,219) | (1,569) |
The principal restructuring expenses included in other operating expenses for 2007 amount to €709 million (2006: €408 million), including €506 million related to the integration of the Schering Group (2006: €179 million). Further details of restructuring expenses are given in Note [26.4] .
Other operating expenses for 2007 include a €152 million write-down of intangible assets necessitated by the findings of the BEYOND study on
Betaferon®/Betaseron®. In the previous year, other operating expenses contained write-downs related to development and marketing agreements for the drug alfimeprase and the product Viadur® totaling €60 million and a write-down of €31 million as a result of a change in the plan to expand the chlor-alkali production facilities in Baytown, Texas, U.S.A.
An amount of €362 million (2006: €220 million) relates to a large number of individually immaterial items within the subsidiaries.
back to overview
Other operating expenses for 2007 include a €152 million write-down of intangible assets necessitated by the findings of the BEYOND study on
Betaferon®/Betaseron®. In the previous year, other operating expenses contained write-downs related to development and marketing agreements for the drug alfimeprase and the product Viadur® totaling €60 million and a write-down of €31 million as a result of a change in the plan to expand the chlor-alkali production facilities in Baytown, Texas, U.S.A. An amount of €362 million (2006: €220 million) relates to a large number of individually immaterial items within the subsidiaries.
back to overview
Bookmark this page
E-mail this page
Advanced Search
